Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Silvio-Ken Garattini"'
Autor:
Luca Guarrera, Mami Kurosaki, Silvio-Ken Garattini, Maurizio Gianni’, Gianpiero Fasola, Luca Rossit, Michele Prisciandaro, Maria Di Bartolomeo, Marco Bolis, Paola Rizzo, Claudia Nastasi, Marika Foglia, Adriana Zanetti, Gabriela Paroni, Mineko Terao, Enrico Garattini
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-20 (2023)
Abstract Background Gastric-cancer is a heterogeneous type of neoplastic disease and it lacks appropriate therapeutic options. There is an urgent need for the development of innovative pharmacological strategies, particularly in consideration of the
Externí odkaz:
https://doaj.org/article/afa7a8af41994fcf9273d86fa409c526
Autor:
Arianna Dri, Silvio Ken Garattini, Marika Cinausero, Marianna Macerelli, Martina Fanelli, Fabio Puglisi, Gianpiero Fasola, Paola Ermacora
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 6776-6786 (2022)
The advent of immune checkpoint inhibitors in combination with multitarget tyrosine kinase inhibitors has become a standard first-line treatment for metastatic renal cell cancer. Along with survival improvement, new toxicities have emerged. Such adve
Externí odkaz:
https://doaj.org/article/852616dc40844039a3f0c09a7c5756b4
Autor:
Debora Basile, Gerardo Rosati, Francesca Bergamo, Silvio Ken Garattini, Maria Banzi, Maria Zampino, Silvia Bozzarelli, Paolo Marchetti, Fabio Galli, Francesca Galli, Raffaella Longarini, Alberto Zaniboni, Daris Ferrari, Sabino De Placido, Luca Giovanni Frassineti, Mario Nicolini, Saverio Cinieri, Michele Priscindiaro, Pina Ziranu, Riccardo Caccialanza, Alessandro Pastorino, Stefania Mosconi, Giuseppe Aprile
Publikováno v:
Clinical Colorectal Cancer. 22:190-198
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26f6d88ea64b4d33272c9848fbead2a9
https://doi.org/10.1016/j.clcc.2023.01.004
https://doi.org/10.1016/j.clcc.2023.01.004
Autor:
Debora Basile, Annamaria Parnofiello, Maria Grazia Vitale, Francesco Cortiula, Lorenzo Gerratana, Valentina Fanotto, Camilla Lisanti, Giacomo Pelizzari, Elena Ongaro, Michele Bartoletti, Silvio Ken Garattini, Victoria Josephine Andreotti, Anna Bacco, Donatella Iacono, Marta Bonotto, Mariaelena Casagrande, Paola Ermacora, Fabio Puglisi, Nicoletta Pella, Gianpiero Fasola, Giuseppe Aprile, Giovanni G. Cardellino
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 2, Pp 368-377 (2019)
Abstract Background Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization, impair
Externí odkaz:
https://doaj.org/article/a2790e6e4fbc47f6b1da3b2ceecde791
Autor:
Emanuela Dell’Aquila, Tea Zeppola, Marco Stellato, Francesco Pantano, Mario Scartozzi, Cristina Madaudo, Filippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile, Bruno Vincenzi, Roberto Moretto, Marco Puzzoni, Silvio Ken Garattini, Riccardo Lobefaro, Giuseppe Tonini, Daniele Santini
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 14 (2020)
Background: Due to the relative rarity of small bowel adenocarcinoma (SBA), prospective trials, helping to guide therapeutic decisions, are lacking and the optimal therapy for advanced SBA is unknown. The role of targeted agents, such as anti–epide
Externí odkaz:
https://doaj.org/article/050a211755e94d1bb500f413586ef3c1
Autor:
Mineko Terao, Luca Guarrera, Silvio Ken Garattini, Marika Foglia, Maurizio Gianni, Enrico Garattini
Publikováno v:
Cancer Research. 83:1597-1597
All-trans retinoic acid (ATRA) is used in the treatment of Acute Promyelocytic Leukemia (APL) with exceptional results, inducing long-lasting remissions in 78% of the patients. In previous papers (Bolis M et al., Ann Oncol. 2017, 28:611; Centritto F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e47343525fadbafafa8009f550a9149
https://doi.org/10.1158/1538-7445.am2023-1597
https://doi.org/10.1158/1538-7445.am2023-1597
Autor:
Elena Ongaro, Debora Basile, Lorenzo Gerratana, Fabio Puglisi, Massimo Di Maio, Silvio Ken Garattini, Valentina Fanotto, F. Cortiula, Marcella Montico, Giacomo Pelizzari, C. Lisanti, Marco Audisio, Giovanni Gerardo Cardellino, Donatella Iacono, Gianpiero Fasola, Nicoletta Pella, Giuseppe Aprile, Angela Buonadonna, C. Corvaja, Luisa Foltran
Publikováno v:
Oncologist
Background Monocyte-to-lymphocyte ratio (MLR) and lactate dehydrogenase (LDH) levels are circulating biomarkers that provide information about tumor-related inflammation and immune suppression. This study aimed to evaluate the prognostic role of MLR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4379781846d0bb57bdd94b8c1c9ac675
https://doi.org/10.1634/theoncologist.2019-0780
https://doi.org/10.1634/theoncologist.2019-0780
Autor:
LAURA CAGGIARI, Silvio Ken Garattini, Fabio Puglisi, GIULIA BRISOTTO, Renato Cannizzaro, Mariangela De Zorzi, Agostino Steffan, MARIATERESA CASAROTTO, Vincenzo Canzonieri, Matteo Fassan, VALLI DE RE, Gianmaria Miolo, Sara Lonardi, Silvio Garattini
Publikováno v:
Cancers; Volume 14; Issue 5; Pages: 1266
Trastuzumab is a human epidermal growth factor receptor 2 (HER2) inhibitor used to treat HER2+ metastatic gastric cancer (mGC). The present study aims to investigate the relationship between CDH1 mRNA expression and HER2-positivity in mGC using a mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8a9465f21288e60666023cd0b30dbff
http://hdl.handle.net/11368/3028348
http://hdl.handle.net/11368/3028348
Autor:
Camilla Lisanti, Debora Basile, Silvio Ken Garattini, Annamaria Parnofiello, Carla Corvaja, Francesco Cortiula, Elisa Bertoli, Elena Ongaro, Luisa Foltran, Mariaelena Casagrande, Paola Di Nardo, Giovanni Gerardo Cardellino, Gianpiero Fasola, Angela Buonadonna, Nicoletta Pella, Giuseppe Aprile, Fabio Puglisi
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 175
Background: Emerging data suggest that gender-related immune system composition affects both immune response and efficacy of immunotherapy in cancer patients (pts). This study aimed to investigate the sex-related prognostic role of MLR in metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5212e317d8daabbb651977041f17095d
https://doi.org/10.3390/cancers15010175
https://doi.org/10.3390/cancers15010175
Autor:
Michele Bartoletti, Gianpiero Fasola, Fabio Puglisi, Giuseppe Aprile, Anna Bacco, Lorenzo Gerratana, Silvio Ken Garattini, Valentina Fanotto, Nicoletta Pella, Maria Grazia Vitale, A. Parnofiello, Elena Ongaro, Paola Ermacora, Debora Basile, V.J. Andreotti, F. Cortiula, Mariaelena Casagrande, Giacomo Pelizzari, C. Lisanti, Marta Bonotto, Giovanni Gerardo Cardellino, Donatella Iacono
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 2, Pp 368-377 (2019)
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle
Background Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization, impaired qualit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233646010ca5268ab2d4ee58ad065c20
https://doi.org/10.1002/jcsm.12368
https://doi.org/10.1002/jcsm.12368